Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in the KSA.
Campus
  • Payor
Campus
  • Payor

RSV Burden in Jazan

Five Years’ Experience with Respiratory Syncytial Virus Among Hospitalized Patients: A Retrospective Study from Jazan, Saudi Arabia

📌 Study Design & Setting:

  • Retrospective observational study (2015–2020)
  • Conducted at a tertiary hospital in Jazan, Saudi Arabia
  • 195 RSV-positive hospitalized cases analyzed

🎯 Study Objectives:

  • Understand RSV burden in hospitalized patients
  • Identify risk factors for ICU admission
  • Analyze seasonal trends & clinical outcomes

👥 Study Population:

  • Patients with confirmed RSV infections (via rapid antigen tests)
  • Exclusions: Other infections or repeated RSV-positive cases

Distribution of RSV cases during the studied years.

Monthly variations revealed a U-shaped pattern with most cases reported during January

Figure 2 Number of RSV cases during the months of the studied period.

The burden of Respiratory Syncytial Virus (RSV) among infants in Saudi Arabia is significant and presents unpredictable risks that can adversely affect both healthy full-term infants and preterm infants. This observation is consistent with existing data from Europe

📊 Total RSV Cases: 195

👶 Gestational Age Distribution:

  • Full-term births: 81.54% (159 patients)
  • Preterm births: 16.92% (33 patients)

RSV infection is one of the important causes of morbidity and intensive care admission among infants and young children in Saudi Arabia


⚠️ ICU Admissions: 31.79% of RSV cases

🏥 Hospitalization Data:

  • Oxygen Support: 40% of RSV cases required oxygen therapy
  • Average Length of Stay: 8.1 days (ICU patients: 12.13 days)


⚠️ Mortality Rate: 8.72%

🩺 Common Comorbidities (49.23% of cases):

  • Congenital Heart Disease
  • Bronchial Asthma
  • Cerebral Palsy
Read the Full Article

  1. Hall CB, et al. Pediatrics. 2013;132(2):e341-e348.
  2. Arriola CS, et al. J Pediatric Infect Dis Soc. 2020;9(5):587-595. Supplementary Tables 4-6.
  3. Rha B, et al. Pediatrics. 2020;146(1):e20193611.
  4. Thwaites R, et al. Eur J Pediatr. 2020;179(5):791-799.
  5. Sanchez-Luna M, et al. Curr Med Res Opin. 2016;32(4):693-698.
  6. Demont C, et al. BMC Infect Dis. 2021;21(1):730.
  7. Van Summeren JJGT, et al. BMC Infect Dis. 2021;21(1):705.
  8. Hartmann K, et al. J Infect Dis. 2022;jiac137.
  9. Yu, et al. Emerg Infect Dis. 2019;25(6):1127-1135.
  10. Kobayashi, et al. Ped Intl. 2021;0:1-7. e (Osman, Alaa adeen et al. 2023)
MAT-BH-2500178 V1 April 2025